آلبندازول
Albendazole (Albenza)
آلبندازول

نام ژنریک

Albendazole

شکل دارویی

اشكال دارويي:


Tablet, Chewable: 200, 400mg


Suspension: 200 mg/5ml

موارد مصرف

موارد و مقدار مصرف


الف) نوروسيستي سركوزيس: دارو از راه خوراكي مصرف مي‌شود.


kg60 < : مقدار mg/kg/day 15 در دو دوز منقسم (حداكثر mg 800 در روز) و به مدت 30-8 روز مصرف مي‌شود.


kg60 : مقدار mg/day 800 در دو دوز منقسم به مدت 30-8 روز تجويز مي‌شود.


نكته: لازم است در هفتة اول درمان به طور همزمان از تركيبات ضد تشنج و استروئيد استفاده شود.


ب) كيست‌هيداتيك: دارو از راه خوراكي مصرف مي‌شود.


kg60 < : مقدار mg/kg/day 15 در دو دوز منقسم (حداكثر mg 800) تجويز مي‌شود.


kg60: مقدار mg/day 800 در دو دوز منقسم مصرف مي‌شود.


نكته: دارو در 3 دوره 28 روزه مصرف مي‌شود كه بين دوره‌ها 14 روز فاصله است.


پ) آنكيلوستوماكانينوم، آسكاريس لومبريكوئيد، آنكيلوستومادئودوناله، و نكتار آمريكانوس: از راه خوراكي، ميزان mg 400 به صورت تك دوز مصرف مي‌شود.


ت) Clonorchis Sinensis: دارو از راه خوراكي و به ميزان mg/kg 10 به مدت 7 روز مصرف مي‌شود.


ث) لارو مهاجر پوستي: مقدار mg 400 يك بار در روز و به مدت 3 روز تجويز مي‌شود.


ج) Enterobius Vermicularis: مقدار mg 400 از دارو از راه خوراكي به صورت دوز منفرد مصرف شده، كه مي‌توان دوز را 2 هفته بعد تكرار نمود.


چ) Gnathostoma Spinigerum: ميزان mg/day 800، در دو دوز منقسم به مدت 21 روز تجويز مي‌شود.


ح) Gongylonemiasis: از راه خوراكي مقدار mg/kg 10 در روز و به مدت 3 روز تجويز مي‌شود.


خ) Mansonella Perstans: ميزان mg/day 800، در دو دوز منقسم به مدت 10 روز مصرف مي‌شود.


د) لارو مهاجر احشايي (توكسو كاريازيس): از راه خوراكي مقدار
mg/day 800 در دو دوز منقسم براي 5 روز تجويز مي‌شود.


ذ) Cysticercus Cellulosae: مقدار mg/day 800 در دو دوز منقسم به مدت 30-8 روز تجويز مي‌‌شود؛ ممكن است مصرف دارو در صورت نياز تكرار گردد.


س) ميكروسپوريديوز منتشر: مقدار mg/day 800 در دو دوز منقسم مصرف مي‌شود.


ش) Echinococcus Granulosus: از راه خوراكي، مقدار mg/day 800 در دو دوز منقسم براي مدت 6-1 ماه تجويز مي‌شود.


ص) ميكروسپوريديوز روده‌اي: مقدار mg/day 800 در دو دوز منقسم به مدت 21 روز مصرف مي‌گردد.


ض) ميكروسپوريديوز چشمي: از راه خوراكي به ميزان mg/day 800، در دو دوز منقسم و همراه با Fumagillin تجويز مي‌گردد.

موارد منع مصرف

موارد منع مصرف و احتياط


موارد منع مصرف: در صورت حساسيت مفرط به آلبندازول، تركيبات بنزيميدازول يا هر يك از اجزاي فرمولاسيون استفاده از اين دارو ممنوع است.


موارد احتياط: به دليل وجود خطر سركوب مغز استخوان، بايستي در بيماران دچار نارسايي كبدي استفاده از اين دارو با احتياط صورت گيرد. (در صورت بروز سركوب شديد مغز استخوان بايد مصرف دارو متوقف گردد).


بيماراني كه افزايش آنزيم‌هاي كبدي و يا اكينوكوكوز كبدي دارند، در معرض خطر هپاتوتوكسيسيته با اين دارو قرار دارند و لازم است در صورت افزايش بيش از دو برابر نرمال آنزيم‌هاي كبدي، مصرف دارو قطع شده و بعد از برگشت به حالت نرمال، مجدداً درمان شروع مي‌شود.


در صورت افت قابل توجه سلولهاي خوني لازم است مصرف دارو بلافاصله قطع شود.

عوارض جانبی دارو

عوارض جانبي


اعصاب مرکزي: سردرد، افزايش فشار داخل جمجمه، گيجي، تب، سرگيجه، علائم مننژه.


كبد: افزايش آنزيم‌هاي كبدي، نارسايي حاد كبدي، هپاتيت.


خون: آنمي آپلاستيك، آگرانولوسيتوز، گرانولوسيتوپني، لكوپني، نوتروپني، پان‌سيتوپني، ترومبوسيتوپني.


پوست: آلوپسي، اريتم مولتي‌فرم،‌ راش، سندرم استيونس جانسون، كهير.


دستگاه گوارش: درد شكمي، تهوع، استفراغ.


ساير عوارض: نارسايي حاد كليوي، واكنش ازدياد حساسيت.

موارد قابل توجه

-

تداخل دارویی

تداخل دارويي


آمينوكينولونها (داروهاي ضد مالاريا) مي‌توانند منجر به كاهش غلظت سرمي تركيبات ضد كرم شوند و لازم است در صورت مصرف همزمان درمان پيگيري شود.

مکانیزم اثر

تداخل دارويي


آمينوكينولونها (داروهاي ضد مالاريا) مي‌توانند منجر به كاهش غلظت سرمي تركيبات ضد كرم شوند و لازم است در صورت مصرف همزمان درمان پيگيري شود.

فارماكوكینتیك

فارماكوكينتيك


جذب: دارو از راه خوراكي جذب ضعيفي دارد و هنگامي كه با غذاهاي چرب مصرف مي‌شود ميزان جذب تا 5 برابر افزايش پيدا مي‌كند.


پخش: دارو توزيع خوبي در داخل كيست هيداتيك و CSF دارد.


متابوليسم: دارو توسط كبد متابوليزه شده و داراي عبور اول كبدي گسترده‌اي مي‌باشد.


مسيرهاي متابوليسمي عبارتند از: سولفوكسيداسيون سريع به متابوليت فعال (آلبندازول سولفوكسايد كه متابوليت اصلي است)، هيدروليز و اكسيداسيون.


دفع: دارو از راه ادرار (كمتر از 1% به شكل متابوليت فعال) و مدفوع دفع مي‌شود.

سایر اطلاعات

طبقه‌بندي فارماكولوژيك: ضد كرم.


طبقه‌بندي درماني : ضد كرم.


طبقه‌بندي مصرف در بارداري: رده C


نام‌هاي تجاري: Bendex


ملاحظات اختصاصي


1- از آنجايي كه موارد كشنده (ولي نادر) آگرانولوسيتوز، آنمي آپلاستيك، گرانولوسيتوپني، لكوپني و پان‌سيتوپني با آلبندازول گزارش شده است، لازم است CBC بيمار پيگيري شده و در صورت افت قابل توجه سلولهاي خوني مصرف دارو بلافاصله متوقف گردد.


2- به دليل اثرات كبدي دارو، لازم است آنزيم‌هاي كبدي پيگيري شده و در صورت افزايش بيش از دو برابر نرمال در سطح اين آنزيم‌ها مصرف دارو متوقف شده و پس از برگشت آنها به حد طبيعي، درمان مجدداً‌ آغاز مي‌گردد.


3- در موارد نوروسركوزيس بايستي قبل يا هنگام شروع آلبندازول، براي بيمار كورتيكوستروئيد نيز تجويز گردد، تا ميزان واكنش‌هاي التهابي به حداقل رسيده و از هايپرتانسيون مغزي جلوگيري شود. به علاوه درمان ضد تشنج در طي هفته اول درمان ضرورت دارد تا از بروز تشنج جلوگيري گردد.


4- در موارد وجود ضايعات شبكيه، بايستي منافع مصرف دارو را در مقابل خطر آسيب چشمي ناشي از آلبندازول سنجيد.


5- سطح سرمي آلبندازول در صورت مصرف با غذاهاي چرب افزايش مي‌يابد و زيست دستيابي دارو تا 5 برابر بالا مي‌رود.


6- لازم است بعد از شروع درمان، به مدت 3 هفته نمونه مدفوع بيمار از نظر تخم و انگل بررسي شده و در صورت مثبت بودن، درمان تكرار شود.


7- بايستي CBC و LFT در شروع هر سيكل 28 روزه درمان انجام شده و هر 2 هفته در طي درمان تكرار شود (در صورت وجود بيماري كبدي، دفعات انجام تست بيشتر خواهد بود.).


8- لازم است قبل از شروع درمان،‌ تست بارداري در خانمها انجام گيرد.


مصرف در شيردهي: ميزان ورود دارو در شير مشخص نيست و مصرف آن در دوران شيردهي توصيه نمي‌شود .


مصرف در بارداري: در مطالعات حيواني مشخص شده كه آلبندازول خواص تراتوژنيك داشته و نبايد در حين دوران بارداري،‌ در صورت امكان، استفاده گردد.


بايستي به خانمها توصيه شود كه به مدت حداقل يك ماه بعد از خاتمه درمان از باردار شدن پرهيز كنند.


در صورت بروز بارداري حين درمان،‌ لازم است درمان متوقف شود.


اثر بر آزمايشهاي تشخيصي


اين دارو مي‌تواند منجر به افزايش سطح آنزيم‌هاي كبدي و سركوب مغز استخوان شود و لازم است حين درمان با اين دارو LFT و CBC پيگيري شود.

Albendazole (Albenza)

ALBENZA®
(albendazole) Tablets

DRUG DESCRIPTION

ALBENZA (albendazole) is an orally administered broad-spectrum anthelmintic. Chemically, it is methyl 5-(propylthio)-2-benzimidazolecarbamate. Its molecular formula is C12H15N3O2S. Its molecular weight is 265.34. It has the following chemical structure:

ALBENZA® (albendazole)  Structural Formula Illustration

Albendazole is a white to off-white powder. It is soluble in dimethylsulfoxide, strong acids, and strong bases. It is slightly soluble in methanol, chloroform, ethyl acetate, and acetonitrile. Albendazole is practically insoluble in water. Each white to off-white, film-coated tablet contains 200 mg of albendazole.

Inactive ingredients consist of: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, sodium lauryl sulfate, sodium saccharin, sodium starch glycolate, and starch.

What are the possible side effects of albendazole (Albenza)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

  • easy bruising or bleeding, unusual weakness;
  • fever, sore throat, and headache with a severe blistering, peeling, and red skin rash; or
  • fever with chills, body aches, or flu-like symptoms.

Less serious side effects may include:

  • stomach pain;
  • nausea, vomiting;
  • headache, dizziness;...

Read All Potential Side Effects and See Pictures of Albenza »

What are the precautions when taking albendazole (Albenza)?

Before taking albendazole, tell your doctor or pharmacist if you are allergic to it; or to other benzimidazole anthelmintic drugs (e.g., mebendazole); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease, biliary tract problems (e.g., blockage), blood/bone marrow disorders.

This medication may cause liver problems. Because drinking alcohol increases the risk of liver problems, limit alcoholic beverages while using this medication. Check with your doctor or pharmacist for more information.

During pregnancy, this medication should be...

Read All Potential Precautions of Albenza »

Last reviewed on RxList: 11/9/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

ALBENZA (albendazole) is indicated for the treatment of the following infections:

Neurocysticercosis

ALBENZA (albendazole) is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. Clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts.

Hydatid Disease

ALBENZA (albendazole) is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

This indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80-90% of patients given ALBENZA (albendazole) for 3 cycles of therapy of 28 days each (see DOSAGE AND ADMINISTRATION). Clinical cure (disappearance of cysts) was seen in approximately 30% of these patients, and improvement (reduction in cyst diameter of ≥ 25%) was seen in an additional 40%.

NOTE: When medically feasible, surgery is considered the treatment of choice for hydatid disease. When administering ALBENZA (albendazole) in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

NOTE: The efficacy of albendazole in the therapy of alveolar hydatid disease caused by Echinococcus multilocularis has not been clearly demonstrated in clinical studies.

DOSAGE AND ADMINISTRATION

Dosing of ALBENZA (albendazole) will vary, depending upon which of the following parasitic infections is being treated. In young children, the tablets should be crushed or chewed and swallowed with a drink of water.

Indication Patient Weight Dose Duration
Hydatid Disease 60 kg or greater 400 mg twice daily, with meals 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)
NOTE: When administering ALBENZA in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
Neurocysticercosis 60 kg or greater 400 mg twice daily, with meals 8-30 days
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

HOW SUPPLIED

ALBENZA (albendazole) is supplied as 200 mg, white to off-white, circular, biconvex, bevel-edged, film-coated TILTAB tablets in bottles of 112.

NDC 0007-5500-40 Bottles of 112

Store between 20° and 25°C (68° and 77°F).

GlaxoSmithKline, Research Triangle Park, NC 27709. Updated: 2009

Last reviewed on RxList: 11/9/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

ALBENZA (albendazole) is indicated for the treatment of the following infections:

Neurocysticercosis

ALBENZA (albendazole) is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. Clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts.

Hydatid Disease

ALBENZA (albendazole) is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

This indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80-90% of patients given ALBENZA (albendazole) for 3 cycles of therapy of 28 days each (see DOSAGE AND ADMINISTRATION). Clinical cure (disappearance of cysts) was seen in approximately 30% of these patients, and improvement (reduction in cyst diameter of ≥ 25%) was seen in an additional 40%.

NOTE: When medically feasible, surgery is considered the treatment of choice for hydatid disease. When administering ALBENZA (albendazole) in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

NOTE: The efficacy of albendazole in the therapy of alveolar hydatid disease caused by Echinococcus multilocularis has not been clearly demonstrated in clinical studies.

DOSAGE AND ADMINISTRATION

Dosing of ALBENZA (albendazole) will vary, depending upon which of the following parasitic infections is being treated. In young children, the tablets should be crushed or chewed and swallowed with a drink of water.

Indication Patient Weight Dose Duration
Hydatid Disease 60 kg or greater 400 mg twice daily, with meals 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)
NOTE: When administering ALBENZA in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
Neurocysticercosis 60 kg or greater 400 mg twice daily, with meals 8-30 days
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

HOW SUPPLIED

ALBENZA (albendazole) is supplied as 200 mg, white to off-white, circular, biconvex, bevel-edged, film-coated TILTAB tablets in bottles of 112.

NDC 0007-5500-40 Bottles of 112

Store between 20° and 25°C (68° and 77°F).

GlaxoSmithKline, Research Triangle Park, NC 27709. Updated: 2009

Last reviewed on RxList: 11/9/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

ALBENZA (albendazole) is indicated for the treatment of the following infections:

Neurocysticercosis

ALBENZA (albendazole) is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. Clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts.

Hydatid Disease

ALBENZA (albendazole) is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

This indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80-90% of patients given ALBENZA (albendazole) for 3 cycles of therapy of 28 days each (see DOSAGE AND ADMINISTRATION). Clinical cure (disappearance of cysts) was seen in approximately 30% of these patients, and improvement (reduction in cyst diameter of ≥ 25%) was seen in an additional 40%.

NOTE: When medically feasible, surgery is considered the treatment of choice for hydatid disease. When administering ALBENZA (albendazole) in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

NOTE: The efficacy of albendazole in the therapy of alveolar hydatid disease caused by Echinococcus multilocularis has not been clearly demonstrated in clinical studies.

DOSAGE AND ADMINISTRATION

Dosing of ALBENZA (albendazole) will vary, depending upon which of the following parasitic infections is being treated. In young children, the tablets should be crushed or chewed and swallowed with a drink of water.

Indication Patient Weight Dose Duration
Hydatid Disease 60 kg or greater 400 mg twice daily, with meals 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)
NOTE: When administering ALBENZA in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
Neurocysticercosis 60 kg or greater 400 mg twice daily, with meals 8-30 days
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

HOW SUPPLIED

ALBENZA (albendazole) is supplied as 200 mg, white to off-white, circular, biconvex, bevel-edged, film-coated TILTAB tablets in bottles of 112.

NDC 0007-5500-40 Bottles of 112

Store between 20° and 25°C (68° and 77°F).

GlaxoSmithKline, Research Triangle Park, NC 27709. Updated: 2009

Last reviewed on RxList: 11/9/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

ALBENZA (albendazole) is indicated for the treatment of the following infections:

Neurocysticercosis

ALBENZA (albendazole) is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. Clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts.

Hydatid Disease

ALBENZA (albendazole) is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

This indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80-90% of patients given ALBENZA (albendazole) for 3 cycles of therapy of 28 days each (see DOSAGE AND ADMINISTRATION). Clinical cure (disappearance of cysts) was seen in approximately 30% of these patients, and improvement (reduction in cyst diameter of ≥ 25%) was seen in an additional 40%.

NOTE: When medically feasible, surgery is considered the treatment of choice for hydatid disease. When administering ALBENZA (albendazole) in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

NOTE: The efficacy of albendazole in the therapy of alveolar hydatid disease caused by Echinococcus multilocularis has not been clearly demonstrated in clinical studies.

DOSAGE AND ADMINISTRATION

Dosing of ALBENZA (albendazole) will vary, depending upon which of the following parasitic infections is being treated. In young children, the tablets should be crushed or chewed and swallowed with a drink of water.

Indication Patient Weight Dose Duration
Hydatid Disease 60 kg or greater 400 mg twice daily, with meals 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)
NOTE: When administering ALBENZA in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
Neurocysticercosis 60 kg or greater 400 mg twice daily, with meals 8-30 days
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

HOW SUPPLIED

ALBENZA (albendazole) is supplied as 200 mg, white to off-white, circular, biconvex, bevel-edged, film-coated TILTAB tablets in bottles of 112.

NDC 0007-5500-40 Bottles of 112

Store between 20° and 25°C (68° and 77°F).

GlaxoSmithKline, Research Triangle Park, NC 27709. Updated: 2009

Last reviewed on RxList: 11/9/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

ALBENZA (albendazole) is indicated for the treatment of the following infections:

Neurocysticercosis

ALBENZA (albendazole) is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. Clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts.

Hydatid Disease

ALBENZA (albendazole) is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

This indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80-90% of patients given ALBENZA (albendazole) for 3 cycles of therapy of 28 days each (see DOSAGE AND ADMINISTRATION). Clinical cure (disappearance of cysts) was seen in approximately 30% of these patients, and improvement (reduction in cyst diameter of ≥ 25%) was seen in an additional 40%.

NOTE: When medically feasible, surgery is considered the treatment of choice for hydatid disease. When administering ALBENZA (albendazole) in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

NOTE: The efficacy of albendazole in the therapy of alveolar hydatid disease caused by Echinococcus multilocularis has not been clearly demonstrated in clinical studies.

DOSAGE AND ADMINISTRATION

Dosing of ALBENZA (albendazole) will vary, depending upon which of the following parasitic infections is being treated. In young children, the tablets should be crushed or chewed and swallowed with a drink of water.

Indication Patient Weight Dose Duration
Hydatid Disease 60 kg or greater 400 mg twice daily, with meals 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)
NOTE: When administering ALBENZA in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
Neurocysticercosis 60 kg or greater 400 mg twice daily, with meals 8-30 days
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

HOW SUPPLIED

ALBENZA (albendazole) is supplied as 200 mg, white to off-white, circular, biconvex, bevel-edged, film-coated TILTAB tablets in bottles of 112.

NDC 0007-5500-40 Bottles of 112

Store between 20° and 25°C (68° and 77°F).

GlaxoSmithKline, Research Triangle Park, NC 27709. Updated: 2009

Last reviewed on RxList: 11/9/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

ALBENZA (albendazole) is indicated for the treatment of the following infections:

Neurocysticercosis

ALBENZA (albendazole) is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. Clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts.

Hydatid Disease

ALBENZA (albendazole) is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

This indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80-90% of patients given ALBENZA (albendazole) for 3 cycles of therapy of 28 days each (see DOSAGE AND ADMINISTRATION). Clinical cure (disappearance of cysts) was seen in approximately 30% of these patients, and improvement (reduction in cyst diameter of ≥ 25%) was seen in an additional 40%.

NOTE: When medically feasible, surgery is considered the treatment of choice for hydatid disease. When administering ALBENZA (albendazole) in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

NOTE: The efficacy of albendazole in the therapy of alveolar hydatid disease caused by Echinococcus multilocularis has not been clearly demonstrated in clinical studies.

DOSAGE AND ADMINISTRATION

Dosing of ALBENZA (albendazole) will vary, depending upon which of the following parasitic infections is being treated. In young children, the tablets should be crushed or chewed and swallowed with a drink of water.

Indication Patient Weight Dose Duration
Hydatid Disease 60 kg or greater 400 mg twice daily, with meals 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)
NOTE: When administering ALBENZA in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
Neurocysticercosis 60 kg or greater 400 mg twice daily, with meals 8-30 days
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

HOW SUPPLIED

ALBENZA (albendazole) is supplied as 200 mg, white to off-white, circular, biconvex, bevel-edged, film-coated TILTAB tablets in bottles of 112.

NDC 0007-5500-40 Bottles of 112

Store between 20° and 25°C (68° and 77°F).

GlaxoSmithKline, Research Triangle Park, NC 27709. Updated: 2009

Last reviewed on RxList: 11/9/2009
This monograph has been modified to include the generic and brand name in many instances.

>

INDICATIONS

ALBENZA (albendazole) is indicated for the treatment of the following infections:

Neurocysticercosis

ALBENZA (albendazole) is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. Clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts.

Hydatid Disease

ALBENZA (albendazole) is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

This indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80-90% of patients given ALBENZA (albendazole) for 3 cycles of therapy of 28 days each (see DOSAGE AND ADMINISTRATION). Clinical cure (disappearance of cysts) was seen in approximately 30% of these patients, and improvement (reduction in cyst diameter of ≥ 25%) was seen in an additional 40%.

NOTE: When medically feasible, surgery is considered the treatment of choice for hydatid disease. When administering ALBENZA (albendazole) in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

NOTE: The efficacy of albendazole in the therapy of alveolar hydatid disease caused by Echinococcus multilocularis has not been clearly demonstrated in clinical studies.

DOSAGE AND ADMINISTRATION

Dosing of ALBENZA (albendazole) will vary, depending upon which of the following parasitic infections is being treated. In young children, the tablets should be crushed or chewed and swallowed with a drink of water.

Indication Patient Weight Dose Duration
Hydatid Disease 60 kg or greater 400 mg twice daily, with meals 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)
NOTE: When administering ALBENZA in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
Neurocysticercosis 60 kg or greater 400 mg twice daily, with meals 8-30 days
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

HOW SUPPLIED

ALBENZA (albendazole) is supplied as 200 mg, white to off-white, circular, biconvex, bevel-edged, film-coated TILTAB tablets in bottles of 112.

NDC 0007-5500-40 Bottles of 112

Store between 20° and 25°C (68° and 77°F).

GlaxoSmithKline, Research Triangle Park, NC 27709. Updated: 2009

Last reviewed on RxList: 11/9/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

ALBENZA (albendazole) is indicated for the treatment of the following infections:

Neurocysticercosis

ALBENZA (albendazole) is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. Clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts.

Hydatid Disease

ALBENZA (albendazole) is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

This indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80-90% of patients given ALBENZA (albendazole) for 3 cycles of therapy of 28 days each (see DOSAGE AND ADMINISTRATION). Clinical cure (disappearance of cysts) was seen in approximately 30% of these patients, and improvement (reduction in cyst diameter of ≥ 25%) was seen in an additional 40%.

NOTE: When medically feasible, surgery is considered the treatment of choice for hydatid disease. When administering ALBENZA (albendazole) in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

NOTE: The efficacy of albendazole in the therapy of alveolar hydatid disease caused by Echinococcus multilocularis has not been clearly demonstrated in clinical studies.

DOSAGE AND ADMINISTRATION

Dosing of ALBENZA (albendazole) will vary, depending upon which of the following parasitic infections is being treated. In young children, the tablets should be crushed or chewed and swallowed with a drink of water.

Indication Patient Weight Dose Duration
Hydatid Disease 60 kg or greater 400 mg twice daily, with meals 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)
NOTE: When administering ALBENZA in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
Neurocysticercosis 60 kg or greater 400 mg twice daily, with meals 8-30 days
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

HOW SUPPLIED

ALBENZA (albendazole) is supplied as 200 mg, white to off-white, circular, biconvex, bevel-edged, film-coated TILTAB tablets in bottles of 112.

NDC 0007-5500-40 Bottles of 112

Store between 20° and 25°C (68° and 77°F).

GlaxoSmithKline, Research Triangle Park, NC 27709. Updated: 2009

Last reviewed on RxList: 11/9/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

ALBENZA (albendazole) is indicated for the treatment of the following infections:

Neurocysticercosis

ALBENZA (albendazole) is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. Clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts.

Hydatid Disease

ALBENZA (albendazole) is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

This indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80-90% of patients given ALBENZA (albendazole) for 3 cycles of therapy of 28 days each (see DOSAGE AND ADMINISTRATION). Clinical cure (disappearance of cysts) was seen in approximately 30% of these patients, and improvement (reduction in cyst diameter of ≥ 25%) was seen in an additional 40%.

NOTE: When medically feasible, surgery is considered the treatment of choice for hydatid disease. When administering ALBENZA (albendazole) in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

NOTE: The efficacy of albendazole in the therapy of alveolar hydatid disease caused by Echinococcus multilocularis has not been clearly demonstrated in clinical studies.

DOSAGE AND ADMINISTRATION

Dosing of ALBENZA (albendazole) will vary, depending upon which of the following parasitic infections is being treated. In young children, the tablets should be crushed or chewed and swallowed with a drink of water.

Indication Patient Weight Dose Duration
Hydatid Disease 60 kg or greater 400 mg twice daily, with meals 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)
NOTE: When administering ALBENZA in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
Neurocysticercosis 60 kg or greater 400 mg twice daily, with meals 8-30 days
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

HOW SUPPLIED

ALBENZA (albendazole) is supplied as 200 mg, white to off-white, circular, biconvex, bevel-edged, film-coated TILTAB tablets in bottles of 112.

NDC 0007-5500-40 Bottles of 112

Store between 20° and 25°C (68° and 77°F).

GlaxoSmithKline, Research Triangle Park, NC 27709. Updated: 2009

Last reviewed on RxList: 11/9/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

ALBENZA (albendazole) is indicated for the treatment of the following infections:

Neurocysticercosis

ALBENZA (albendazole) is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. Clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts.

Hydatid Disease

ALBENZA (albendazole) is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

This indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80-90% of patients given ALBENZA (albendazole) for 3 cycles of therapy of 28 days each (see DOSAGE AND ADMINISTRATION). Clinical cure (disappearance of cysts) was seen in approximately 30% of these patients, and improvement (reduction in cyst diameter of ≥ 25%) was seen in an additional 40%.

NOTE: When medically feasible, surgery is considered the treatment of choice for hydatid disease. When administering ALBENZA (albendazole) in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

NOTE: The efficacy of albendazole in the therapy of alveolar hydatid disease caused by Echinococcus multilocularis has not been clearly demonstrated in clinical studies.

DOSAGE AND ADMINISTRATION

Dosing of ALBENZA (albendazole) will vary, depending upon which of the following parasitic infections is being treated. In young children, the tablets should be crushed or chewed and swallowed with a drink of water.

Indication Patient Weight Dose Duration
Hydatid Disease 60 kg or greater 400 mg twice daily, with meals 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)
NOTE: When administering ALBENZA in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
Neurocysticercosis 60 kg or greater 400 mg twice daily, with meals 8-30 days
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

HOW SUPPLIED

ALBENZA (albendazole) is supplied as 200 mg, white to off-white, circular, biconvex, bevel-edged, film-coated TILTAB tablets in bottles of 112.

NDC 0007-5500-40 Bottles of 112

Store between 20° and 25°C (68° and 77°F).

GlaxoSmithKline, Research Triangle Park, NC 27709. Updated: 2009

Last reviewed on RxList: 11/9/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

ALBENZA (albendazole) is indicated for the treatment of the following infections:

Neurocysticercosis

ALBENZA (albendazole) is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. Clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts.

Hydatid Disease

ALBENZA (albendazole) is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

This indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80-90% of patients given ALBENZA (albendazole) for 3 cycles of therapy of 28 days each (see DOSAGE AND ADMINISTRATION). Clinical cure (disappearance of cysts) was seen in approximately 30% of these patients, and improvement (reduction in cyst diameter of ≥ 25%) was seen in an additional 40%.

NOTE: When medically feasible, surgery is considered the treatment of choice for hydatid disease. When administering ALBENZA (albendazole) in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

NOTE: The efficacy of albendazole in the therapy of alveolar hydatid disease caused by Echinococcus multilocularis has not been clearly demonstrated in clinical studies.

DOSAGE AND ADMINISTRATION

Dosing of ALBENZA (albendazole) will vary, depending upon which of the following parasitic infections is being treated. In young children, the tablets should be crushed or chewed and swallowed with a drink of water.

Indication Patient Weight Dose Duration
Hydatid Disease 60 kg or greater 400 mg twice daily, with meals 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)
NOTE: When administering ALBENZA in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
Neurocysticercosis 60 kg or greater 400 mg twice daily, with meals 8-30 days
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

HOW SUPPLIED

ALBENZA (albendazole) is supplied as 200 mg, white to off-white, circular, biconvex, bevel-edged, film-coated TILTAB tablets in bottles of 112.

NDC 0007-5500-40 Bottles of 112

Store between 20° and 25°C (68° and 77°F).

GlaxoSmithKline, Research Triangle Park, NC 27709. Updated: 2009

Last reviewed on RxList: 11/9/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

ALBENZA (albendazole) is indicated for the treatment of the following infections:

Neurocysticercosis

ALBENZA (albendazole) is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. Clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts.

Hydatid Disease

ALBENZA (albendazole) is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

This indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80-90% of patients given ALBENZA (albendazole) for 3 cycles of therapy of 28 days each (see DOSAGE AND ADMINISTRATION). Clinical cure (disappearance of cysts) was seen in approximately 30% of these patients, and improvement (reduction in cyst diameter of ≥ 25%) was seen in an additional 40%.

NOTE: When medically feasible, surgery is considered the treatment of choice for hydatid disease. When administering ALBENZA (albendazole) in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

NOTE: The efficacy of albendazole in the therapy of alveolar hydatid disease caused by Echinococcus multilocularis has not been clearly demonstrated in clinical studies.

DOSAGE AND ADMINISTRATION

Dosing of ALBENZA (albendazole) will vary, depending upon which of the following parasitic infections is being treated. In young children, the tablets should be crushed or chewed and swallowed with a drink of water.

Indication Patient Weight Dose Duration
Hydatid Disease 60 kg or greater 400 mg twice daily, with meals 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)
NOTE: When administering ALBENZA in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
Neurocysticercosis 60 kg or greater 400 mg twice daily, with meals 8-30 days
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

HOW SUPPLIED

ALBENZA (albendazole) is supplied as 200 mg, white to off-white, circular, biconvex, bevel-edged, film-coated TILTAB tablets in bottles of 112.

NDC 0007-5500-40 Bottles of 112

Store between 20° and 25°C (68° and 77°F).

GlaxoSmithKline, Research Triangle Park, NC 27709. Updated: 2009

Last reviewed on RxList: 11/9/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

ALBENZA (albendazole) is indicated for the treatment of the following infections:

Neurocysticercosis

ALBENZA (albendazole) is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. Clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts.

Hydatid Disease

ALBENZA (albendazole) is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

This indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80-90% of patients given ALBENZA (albendazole) for 3 cycles of therapy of 28 days each (see DOSAGE AND ADMINISTRATION). Clinical cure (disappearance of cysts) was seen in approximately 30% of these patients, and improvement (reduction in cyst diameter of ≥ 25%) was seen in an additional 40%.

NOTE: When medically feasible, surgery is considered the treatment of choice for hydatid disease. When administering ALBENZA (albendazole) in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

NOTE: The efficacy of albendazole in the therapy of alveolar hydatid disease caused by Echinococcus multilocularis has not been clearly demonstrated in clinical studies.

DOSAGE AND ADMINISTRATION

Dosing of ALBENZA (albendazole) will vary, depending upon which of the following parasitic infections is being treated. In young children, the tablets should be crushed or chewed and swallowed with a drink of water.

Indication Patient Weight Dose Duration
Hydatid Disease 60 kg or greater 400 mg twice daily, with meals 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)
NOTE: When administering ALBENZA in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
Neurocysticercosis 60 kg or greater 400 mg twice daily, with meals 8-30 days
less than 60 kg 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg)

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

HOW SUPPLIED

ALBENZA (albendazole) is supplied as 200 mg, white to off-white, circular, biconvex, bevel-edged, film-coated TILTAB tablets in bottles of 112.

NDC 0007-5500-40 Bottles of 112

Store between 20° and 25°C (68° and 77°F).

GlaxoSmithKline, Research Triangle Park, NC 27709. Updated: 2009

Last reviewed on RxList: 11/9/2009
This monograph has been modified to include the generic and brand name in many instances.

توزیع کنندگان این دارو
شرکت های تولید کننده یا وارد کننده دارو

دارونـــما
نوآوری برای سلامت

طراحی و اجرا M.Ramezani
ارتباط با ما Info@darunama.com